The association of oral hydroxyurea therapy with improved cognitive functioning in Sickle Cell Disease
The association of oral hydroxyurea therapy with improved cognitive functioning in Sickle Cell Disease
复制标题
DOI：
10.1080/09297040600584626
复制
发表时间：
2007-03-01
影响因子：
2.2
通讯作者：
Roberts, Carla W.
中科院分区：
文献类型：
--
作者：
Puffer, Eve;Schatz, Jeffrey;Roberts, Carla W.
本研究探讨了口服羟基脲治疗对镰状细胞病（SCD）儿童的潜在认知益处。将15名接受羟基脲治疗的SCD儿童的认知能力与其他50名SCD儿童进行比较，控制人口统计学和红细胞压积。服用羟基脲的儿童在语言理解、流体推理和一般认知能力测试中的得分显著高于未服用药物的儿童。因此，这些数据为羟基脲的认知益处提供了初步证据。这种效应的机制可能是改善大脑的血液/氧气供应或减少疲劳和疾病。
This study examined potential cognitive benefits of oral hydroxyurea therapy for children with sickle cell disease (SCD). Cognitive abilities of 15 children with SCD on hydroxyurea were compared to 50 other children with SCD, controlling for demographics and hematocrit. Children on hydroxyurea scored significantly higher on tests of verbal comprehension, fluid reasoning, and general cognitive ability than children not on the drug. The data therefore provide preliminary evidence of cognitive benefits of hydroxyurea. Mechanisms for this effect may be improved blood/oxygen supply to the brain or reduced fatigue and illness.